Pacific Edge - Latest News [Page 1]

Pacific Edge Appoints Charles Sitch as Independent Director

Friday, 19 September 2014, 4:10 pm | Pacific Edge

Pacific Edge is pleased to announce the appointment of Charles Sitch as an Independent Director. More >>

US grants Pacific Edge patent for melanoma detection

Thursday, 4 September 2014, 2:20 pm | Pacific Edge

The United States Patent Office has granted Pacific Edge patent protection for 'Prognosis Prediction for Melanoma'. The patent covers the technology being used to develop the melanoma prognostic test that will enable clinicians to distinguish aggressive ... More >>

Kaiser Permanente signs up for Cxbladder

Wednesday, 27 August 2014, 12:05 pm | Pacific Edge

Pacific Edge Ltd has signed an agreement with Southern California Permanente Medical Group (SCPMG) to research its User Program to evaluate its bladder cancer technology Cxbladder within the clinical settings of Kaiser Permanente’s health care network. More >>

Pacific Edge AGM addresses

Friday, 22 August 2014, 5:05 pm | Pacific Edge

Chairman and CEO addresses to the Pacific Edge annual shareholders meeting held in Dunedin late Thursday afternoon. More >>

Building Presence in World’s Largest Biomedical Market

Friday, 22 August 2014, 10:26 am | Pacific Edge

At its annual shareholders’ meeting held yesterday in Dunedin, New Zealand, cancer diagnostic developer, Pacific Edge, celebrated the commercial launch of its flagship bladder cancer diagnostic product, Cxbladder, into the US and provided shareholders ... More >>

Bladder cancer testing service goes live in NZ

Tuesday, 29 July 2014, 12:06 pm | Pacific Edge

All New Zealand residents and healthcare professionals can today access the Cxbladder cancer detection technology developed by Dunedin-based Pacific Edge with the ‘go live’ of an e-commerce platform. http://www.cxbladder.com/order-form More >>

FY14 Marks Significant Commercial Milestone for Pacific Edge

Wednesday, 28 May 2014, 2:03 pm | Pacific Edge

The 2014 Financial Year marked a significant commercial milestone for Pacific Edge as the Company celebrated the start of revenue generation in its primary market, the USA, alongside a strong year of market development and customer capture. More >>

Pacific Edge signs Cxbladder agreement with MultiPlan

Monday, 26 May 2014, 10:38 am | Pacific Edge

Pacific Edge announced today that it has entered into a contractual agreement with MultiPlan, Inc. for diagnostics laboratory testing. The agreement includes Pacific Edge’s participation in the MultiPlan, PHCS and PHCS Savility Networks. More >>

Pacific Edge named Top Bioscience Company in 2014

Friday, 2 May 2014, 11:35 am | Pacific Edge

Pacific Edge has been named NZBIO’s top bioscience company for 2014. Pacific Edge was specifically recognised for building the profile and credibility of biotechnology and biotechnology companies in New Zealand. More >>

Callaghan Grant accelerates Cxbladder development

Thursday, 27 February 2014, 10:40 am | Pacific Edge

Pacific Edge is delighted to have the support of Callaghan Innovation to further accelerate the development of its molecular cancer detection technology. More >>

Commercial agreement for entry of Cxbladder to DHBs

Monday, 10 February 2014, 3:27 pm | Pacific Edge

10 February 2014 Health Innovation Hub signs commercial agreement for entry of Cxbladder to DHBs More >>

Pacific Edge shareholder rights offer closes

Thursday, 28 November 2013, 2:33 pm | Pacific Edge

Pacific Edge’s 2 for 15 pro rata renounceable rights offer of new Pacific Edge shares (“New Shares”) closed yesterday. More >>

PE signs Cxbladder agreement with 3rd national provider-US

Thursday, 28 November 2013, 12:33 pm | Pacific Edge

Pacific Edge has signed an agreement with Stratose, a large national provider network in the USA, to enable the provision of Cxbladder to patients through its large network of payers and providers. Stratose, one of the largest directly managed participating ... More >>

Pacific Edge - 2:15 pro-rata renounceable rights issue

Wednesday, 23 October 2013, 2:19 pm | Pacific Edge

Pacific Edge (NZX:PEB) announces a pro-rata renounceable rights issue to raise up to $20.5 million to further fund the roll out of its high performing cancer diagnostic system Cxbladder in the world’s largest health market, the USA. More >>

Pacific Edge signs agreement with American Network

Tuesday, 22 October 2013, 10:41 am | Pacific Edge

Pacific Edge signs agreement with America’s Choice Provider Network to expand access to Cxbladder in the US More >>

Cxbladder is Supreme Winner at NZ Innovators Awards

Friday, 18 October 2013, 1:02 pm | Pacific Edge

Pacific Edge is the 2013 Supreme Winner of the NZ Innovators Award for Cxbladder, its novel gene test for the detection and management of bladder cancer.' More >>

First Commercial Sales Achieved for Cxbladder in the USA

Friday, 18 October 2013, 11:52 am | Pacific Edge

Cancer diagnostic specialist Pacific Edge (NZX:PEB) is delighted to announce that it has completed the first commercial sales of Cxbladder tests signalling the start of the commercial revenue for the company in the US. The tests were ordered by US ... More >>

40 million Americans provided access to Cxbladder

Wednesday, 16 October 2013, 3:22 pm | Pacific Edge

Pacific Edge (NZX:PEB), a cancer diagnostic company leading in the development and commercialisation of molecular diagnostic tests, has signed an agreement with FedMed, a national preferred provider network in the United States, to make Cxbladder available ... More >>

US accolade with accreditation granted to Pacific Edge NZ

Wednesday, 2 October 2013, 12:09 pm | Pacific Edge

Cancer diagnostic specialist Pacific Edge has joined an elite group of organisations outside the United States with the registration of Pacific Edge Diagnostics’ Dunedin laboratory to conduct Cxbladder tests under the CLIA regulatory process. More >>

Cxbladder excels in New Zealand

Tuesday, 10 September 2013, 11:26 am | Pacific Edge

New Zealand clinicians and healthcare providers are excited about Pacific Edge Limited’s cancer detection system Cxbladder for its ability to detect bladder cancer with a high degree of accuracy. More >>

 

 

InfoPages Links

 
 
 
 
 

LATEST HEADLINES

 
 
 
InfoPages
Search Scoop  
 
 
Powered by Vodafone
NZ independent news